Mankind Pharma (MANKIND) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 revenue grew 12.2% year-on-year to ₹2,893 crore, with adjusted EBITDA margin of 25.2% and PAT margin of 19%.

• Achieved 8.9% YoY growth in domestic business and 61.9% YoY growth in exports; chronic therapies outperformed IPM by 1.3x.

• Completed acquisition of 100% stake in BSV Limited, expanding into super specialty and high entry barrier products; expected to be EPS accretive from the second full year.

• Consumer healthcare business showed sequential recovery with 32% revenue growth; brands maintained leadership in key categories.

• Board approved unaudited standalone and consolidated financial results for Q1 FY25, with unmodified review by auditors.

Financial highlights

• Revenue from operations rose to ₹2,893.42 crore, up 12.2% year-on-year; consolidated net profit was ₹543.07 crore.

• Gross margin improved to 71.9%, up 3.7% year-on-year, driven by price increases and favorable sales mix.

• Adjusted EBITDA was ₹728 crore (25.2% margin); PAT increased to ₹543 crore; diluted EPS at ₹13.4.

• Net cash position stood at ₹3,747 crore as of June 30, 2024; cash flow from operations for Q1 FY25 at ₹546 crore.

• Standalone revenue from operations for Q1 FY25 was ₹2,403.26 crore, with standalone net profit at ₹513.49 crore.

Outlook and guidance

• Retained EBITDA margin guidance of 25%-26% for FY25; R&D expenses expected to remain around 2% of sales.

• CapEx spend to remain at 4%-5% of revenue; BSV business expected to grow at 15%-20% with margins around 30%+.

• BSV acquisition expected to deliver double-digit top-line growth and 30%+ EBITDA margin; synergy benefits of ₹50–100 crore over 12–24 months.

• Net debt/EBITDA to remain below 2x by FY26E.

• Focus on expanding chronic and specialty segments, increasing metro penetration, and leveraging digital platforms.